Brief: Qualigen Therapeutics Receives Orphan Drug Designation From The U.S. Food And Drug Administration For Qn-302, A G-Quadruplex (G4) Transcription Inhibitor For The Intended Indication Of Pancreatic Cancer

Aixcrypto Holdings

10/01/2023 14:11

Jan 10 (Reuters) - Qualigen Therapeutics Inc  QLGN.O :
    * QUALIGEN THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION
FROM THE
U.S. FOOD AND DRUG ADMINISTRATION FOR QN-302, A G-QUADRUPLEX
(G4) TRANSCRIPTION INHIBITOR FOR THE INTENDED INDICATION OF
PANCREATIC CANCER
    * QUALIGEN THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION
FROM THE
U.S. FOOD AND DRUG ADMINISTRATION FOR QN-302, A G-QUADRUPLEX
(G4) TRANSCRIPTION INHIBITOR FOR THE INTENDED INDICATION OF
PANCREATIC CANCER
    * QUALIGEN THERAPEUTICS INC - PREPARE TO SUBMIT OUR IND
APPLICATION IN FIRST HALF OF 2023 FOR OUR PHASE I CLINICAL TRIAL

Source text for Eikon:  ID:nGNX23Zqv7 
Further company coverage:  QLGN.O 
 ((reuters.briefs@thomsonreuters.com;))